David M Weiss1, Robin J Casten2, Benjamin E Leiby3, Lisa A Hark4, Ann P Murchison4, Deiana Johnson1, Shayla Stratford1, Jeffrey Henderer5, Barry W Rovner6, Julia A Haller7. 1. Department of Research, Wills Eye Hospital, Philadelphia, Pennsylvania. 2. Department of Psychiatry and Human Behavior, Thomas Jefferson University, Philadelphia, Pennsylvania. 3. Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania. 4. Department of Research, Wills Eye Hospital, Philadelphia, Pennsylvania4Department of Ophthalmology, Thomas Jefferson University, Wills Eye Hospital, Philadelphia, Pennsylvania. 5. Department of Ophthalmology, Temple University School of Medicine, Philadelphia, Pennsylvania. 6. Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania. 7. Department of Ophthalmology, Thomas Jefferson University, Wills Eye Hospital, Philadelphia, Pennsylvania.
Abstract
IMPORTANCE: African American individuals are at high risk of diabetes mellitus and diabetic retinopathy but have suboptimal rates of dilated fundus examinations (DFEs). Early intervention is crucial for the prevention of diabetic retinopathy in this high-risk population. OBJECTIVE: To test the efficacy of behavioral activation for diabetic retinopathy prevention on rates of DFEs in older African American individuals with diabetes mellitus. DESIGN, SETTING, AND PARTICIPANTS: Masked randomized clinical trial at 2 urban medical centers from October 1, 2010, to May 31, 2014. Participants included 206 African American individuals 65 years and older with diabetes mellitus who had not obtained a DFE in the preceding 12 months. INTERVENTIONS: Participants were randomized to either behavioral activation for diabetic retinopathy prevention, a behavioral intervention designed to provide education, facilitate identifying and addressing health care barriers, and promote goal setting to improve rates of DFEs, or supportive therapy, a control condition. MAIN OUTCOMES AND MEASURES: The primary outcome was medical documentation of a DFE at 6 months' follow-up. Secondary outcomes included the Risk Perceptions and Risk Knowledge Survey of Diabetes Mellitus, Diabetes Self-Care Inventory, Patient Health Questionnaire 9, and National Eye Institute Vision Function Questionnaire 25 scores and hemoglobin A1c levels. RESULTS: More participants in the behavioral activation for diabetic retinopathy prevention group (87.9%) obtained a DFE compared with those in the supportive therapy group (34.1%) by the 6-month follow-up assessment (P < .001). Overall, participants in the behavioral activation for diabetic retinopathy prevention group were 2.5 times more likely to obtain a DFE compared with those in the supportive therapy group (risk ratio = 2.58; 95% CI, 1.91-3.48; P < .001). The intervention had no short-term effect on secondary outcomes of hemoglobinA1c levels, depression, or the Risk Perceptions and Risk Knowledge Survey of Diabetes Mellitus or National Eye Institute Vision Function Questionnaire 25 composite scores; however, both groups had improved adherence to diabetes mellitus self-care behaviors from baseline to 6-month follow-up. CONCLUSIONS AND RELEVANCE: Behavioral activation for diabetic retinopathy prevention significantly increased rates of DFEs in older African American individuals with diabetes mellitus. Behavioral interventions may have the potential to positively affect screening for diabetic retinopathy in at-risk populations. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01179555.
RCT Entities:
IMPORTANCE: African American individuals are at high risk of diabetes mellitus and diabetic retinopathy but have suboptimal rates of dilated fundus examinations (DFEs). Early intervention is crucial for the prevention of diabetic retinopathy in this high-risk population. OBJECTIVE: To test the efficacy of behavioral activation for diabetic retinopathy prevention on rates of DFEs in older African American individuals with diabetes mellitus. DESIGN, SETTING, AND PARTICIPANTS: Masked randomized clinical trial at 2 urban medical centers from October 1, 2010, to May 31, 2014. Participants included 206 African American individuals 65 years and older with diabetes mellitus who had not obtained a DFE in the preceding 12 months. INTERVENTIONS:Participants were randomized to either behavioral activation for diabetic retinopathy prevention, a behavioral intervention designed to provide education, facilitate identifying and addressing health care barriers, and promote goal setting to improve rates of DFEs, or supportive therapy, a control condition. MAIN OUTCOMES AND MEASURES: The primary outcome was medical documentation of a DFE at 6 months' follow-up. Secondary outcomes included the Risk Perceptions and Risk Knowledge Survey of Diabetes Mellitus, Diabetes Self-Care Inventory, Patient Health Questionnaire 9, and National Eye Institute Vision Function Questionnaire 25 scores and hemoglobin A1c levels. RESULTS: More participants in the behavioral activation for diabetic retinopathy prevention group (87.9%) obtained a DFE compared with those in the supportive therapy group (34.1%) by the 6-month follow-up assessment (P < .001). Overall, participants in the behavioral activation for diabetic retinopathy prevention group were 2.5 times more likely to obtain a DFE compared with those in the supportive therapy group (risk ratio = 2.58; 95% CI, 1.91-3.48; P < .001). The intervention had no short-term effect on secondary outcomes of hemoglobin A1c levels, depression, or the Risk Perceptions and Risk Knowledge Survey of Diabetes Mellitus or National Eye Institute Vision Function Questionnaire 25 composite scores; however, both groups had improved adherence to diabetes mellitus self-care behaviors from baseline to 6-month follow-up. CONCLUSIONS AND RELEVANCE: Behavioral activation for diabetic retinopathy prevention significantly increased rates of DFEs in older African American individuals with diabetes mellitus. Behavioral interventions may have the potential to positively affect screening for diabetic retinopathy in at-risk populations. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01179555.
Authors: Nyawira Mwangi; David Macleod; Stephen Gichuhi; Lawrence Muthami; Consuela Moorman; Covadonga Bascaran; Allen Foster Journal: Trop Med Health Date: 2017-12-21
Authors: Fiona Riordan; Emmy Racine; Eunice T Phillip; Colin Bradley; Fabiana Lorencatto; Mark Murphy; Aileen Murphy; John Browne; Susan M Smith; Patricia M Kearney; Sheena M McHugh Journal: Implement Sci Date: 2020-05-19 Impact factor: 7.327
Authors: Zara Khair; Md Moshiur Rahman; Kana Kazawa; Yasmin Jahan; Abu S G Faruque; Mohammod Jobayer Chisti; Michiko Moriyama Journal: PLoS One Date: 2020-11-12 Impact factor: 3.240
Authors: Leonard E Egede; Tatiana M Davidson; Rebecca G Knapp; Rebekah J Walker; Joni S Williams; Clara E Dismuke; Aprill Z Dawson Journal: Trials Date: 2021-11-08 Impact factor: 2.279
Authors: John G Lawrenson; Ella Graham-Rowe; Fabiana Lorencatto; Jennifer Burr; Catey Bunce; Jillian J Francis; Patricia Aluko; Stephen Rice; Luke Vale; Tunde Peto; Justin Presseau; Noah Ivers; Jeremy M Grimshaw Journal: Cochrane Database Syst Rev Date: 2018-01-15
Authors: Stacey L Tannenbaum; Laura A McClure; D Diane Zheng; Byron L Lam; Kristopher L Arheart; Charlotte E Joslin; Gregory A Talavera; David J Lee Journal: BMJ Open Diabetes Res Care Date: 2016-08-10